As part of its 2026 corporate social responsibility agenda, Ashcorp Group carried out an outreach visit to the Sickle Cell Foundation of Nigeria in the lead-up to World Sickle Cell Awareness Day, observed annually on June 19.
The visit focused on engaging directly with the realities of sickle cell disease in Nigeria while supporting ongoing efforts to improve patient care and outcomes. During the visit, the Ashcorp team received a briefing from the Foundation’s staff, toured the facility, and spent time with patients and their families to better understand their experiences.
As part of the engagement, Ashcorp donated medication and essential supplies to support the Foundation’s work and the needs of patients under its care.
Speaking during the visit, Nneka Onita, Corporate Communications Manager at Ashcorp Group, emphasised the company’s approach to impact, noting that growth should extend beyond business performance to include meaningful contributions to society:
“Our visit to the Sickle Cell Foundation is part of our commitment to supporting better health outcomes in line with the United Nations Sustainable Development Goal 3, which focuses on good health and well-being.
Sickle cell disease remains one of the most common genetic conditions globally, with approximately 5 percent of the world’s population carrying the gene for haemoglobin disorders. Nigeria bears the highest burden, with an estimated one in four Nigerians identified as carriers and between 100,000 and 150,000 children born annually with the condition. Efforts like this cannot be occasional. They have to be consistent to make a real difference.”
These figures highlight the importance of sustained awareness, early diagnosis, and access to consistent care. Institutions such as the Sickle Cell Foundation of Nigeria play a critical role in addressing these needs through patient care, education, and family support.
The company noted that this contribution is part of a broader commitment to supporting better health outcomes and engaging with issues that directly affect communities. The company also acknowledged the resilience of patients and families living with sickle cell disease and reaffirmed its intention to maintain a long-term relationship with the Foundation.
